BridgeBio Oncology Therapeutics (BBOT) vs Lexeo Therapeutics (LXEO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lexeo Therapeutics (LXEO) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, losing 60.3% versus a loss of 71.8%. BridgeBio Oncology Therapeutics is the larger company by market cap ($275.8 million vs $271.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBOT | LXEO |
|---|---|---|
| Share price | $3.44 | $3.31 |
| Market cap | $275.80M | $271.71M |
| 1-day change | -1.71% | +0.30% |
| YTD return | -72.52% | -66.67% |
| 1-year return | -71.83% | -60.31% |
| EPS (TTM) | $-0.07 | $-1.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.87 | $10.99 |
| 52-week low | $3.36 | $2.98 |
| Distance from 52-week high | -76.87% | -69.88% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +613.66% | +513.29% |
| Average volume | 468.83K | 1.17M |
| Shares outstanding | 80.17M | 82.09M |
| Employees | 88 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LXEO has outperformed BBOT by 11.5 percentage points over the past year.
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
BBOT vs LXEO FAQ
Which is bigger, BridgeBio Oncology Therapeutics or Lexeo Therapeutics?
BridgeBio Oncology Therapeutics (BBOT) is larger, with a market capitalization of $275.80M compared with $271.71M for Lexeo Therapeutics (LXEO).
Which stock has performed better over the past year, BBOT or LXEO?
LXEO returned -60.31% over the past 12 months, compared with -71.83% for BBOT (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Oncology Therapeutics and Lexeo Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for BridgeBio Oncology Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Lexeo Therapeutics.